Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption  SARASOTA, FLA., Aug.  06, 2026  (GLOBE NEWSWIRE) --  Silo Pharma

SILO

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

Silo Pharma Advances QwikAgents AWS-Native Platform With Caylent Partnership

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption  SARASOTA, FLA., Aug.  06, 2026  (GLOBE NEWSWIRE) --  Silo Pharma</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Silo Pharma announced its QwikAgents subsidiary will collaborate with Caylent to build a new AWS-native platform, preserving core features while boosting scalability, security, and performance for enterprise deployment. The arrangement leverages AWS funding programs and Caylent’s cloud expertise, signaling a potential acceleration in QwikAgents’ commercialization and a broader growth path for SILO’s AI initiatives alongside its biopharma programs.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>QwikAgents to build an AWS-native platform with Caylent, not migrating current app.</li><li>Funding support expected from AWS and Caylent.</li><li>Aims to boost enterprise scalability, performance, security for deployment.</li><li>CEO Weisblum: collaboration positions QwikAgents for enterprise growth.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Silo Pharma, Inc. (SILO)</strong>: Announces collaboration; aims to position QwikAgents for enterprise growth.</li><li><strong>QwikAgents (N/A)</strong>: SILO&#039;s AI subsidiary; will be rebuilt on an AWS-native foundation.</li><li><strong>Caylent (N/A)</strong>: AWS Premier Tier Services Partner leading platform design and build.</li><li><strong>Amazon Web Services (AWS) (N/A)</strong>: Funding programs expected to support the AWS-native development.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. It describes a strategic partnership and platform build that could influence SILO&#039;s growth trajectory and risk-reward profile through potential enterprise revenue and funding support.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>AWS funding alignment could de-risk upfront costs and accelerate enterprise sales.</li><li>Potential for broader monetization of QwikAgents if enterprise deployments succeed.</li><li>Milestone-based updates and funding announcements will drive short-term sentiment.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of release: Aug 6, 2026.</li><li>Company: Silo Pharma, Inc. (SILO) announces QwikAgents collaboration with Caylent.</li><li>QwikAgents is SILO’s wholly owned AI subsidiary.</li><li>Caylent is an AWS Premier Tier Services Partner.</li><li>Platform development goal: build an AWS-native QwikAgents platform (not migrate).</li><li>Funding support expected from AWS and Caylent.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish for SILO if enterprise traction materializes within 6–12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><b><i>Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption</i></b></p>  <p>SARASOTA, FLA., Aug.  06, 2026  (GLOBE NEWSWIRE) --  Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SILO">SILO</a>) ("Silo" or "the Company"), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, a cloud services company and Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform.</p>  <p>The collaboration represents the next phase in the evolution of the QwikAgents platform. Rather than migrating the existing application, Caylent will build a new AWS-native foundation that preserves QwikAgents&#39; core functionality while enhancing scalability, performance and security for enterprise deployment and future product innovation. The engagement is also structured to align with AWS funding programs, with funding support expected from AWS and Caylent.</p>  <p>"This collaboration is an important step in positioning QwikAgents for enterprise growth," said Eric Weisblum, Chief Executive Officer of Silo Pharma. "By combining our AI platform with Caylent&#39;s AWS expertise, we&#39;re creating a scalable foundation to accelerate commercialization and future innovation."</p>  <p>The AWS-native platform is expected to enhance the scalability, performance and security of QwikAgents while accelerating future product development and supporting the platform&#39;s long-term commercialization strategy.</p>  <p><b>About Silo Pharma, Inc.</b></p>  <p><b>QwikAgents</b>, Silo Pharma&#39;s wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation — each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo&#39;s strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. <a href="https://www.globenewswire.com/Tracker?data=9K6NS4ihN_hVXTaR6lpDPDIj4TmCtZJRVcSGtMw7Ap4CHfXbmUGhbiYMycFQ61z2SxtHgjCaJ_zEx0tVitPYLq3BSAsKdnEKUUXygOnkexCL7JXSBF2mHY7SCuBl3SQxlKq7gR-wel1hMlWchCwgYU9HU9CuzSiAaqQcnadbksKMGm5ENoDbqppWOTvzz5tlDPiC-HpPCBd_v6E2MI6YW5qv_2GPR-ccFocmYJuXskQ=" rel="nofollow" target="_blank">qwikagents.com</a></p>  <p><b>Silo Pharma</b> is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. <a href="https://www.globenewswire.com/Tracker?data=SNm6qf9BFWv-jBQKKGlrtpSMZWwn-66SI4xErF1TQmGmcYT6HtnIzYfAUfsE50-2PLB2xAZfdHi1TvurO4MVV2NcrxAsAoHWtEUPiq6WEU-Q1U8cflSq3_ssxqgIQok1yfA0fkcg9_1wSaViRbpsm5CWKDH2HBI7k-DvtgA4cBnPJRZcsXMrOUj7aazp1I8yIEsieb0kP-gEajJSzVae8Z13AGPbHoPToIFoBy_xsqKzfKZ4a0cGIzZBQh21ZqiFFM2NHY6nAumu8lNMWR3ErtcO4g9HxBrI4aNpZfsKfnPUeRcvKnJ4hmRn9WQCn7LdnLf7xd_bm8pyKjEjE_LEz1MVIcRZsjkYsDbrOPlkH5G-jraO4NE92iEuo_QJOU5h76WNS6sqoEkQ0mKB2QzI4NCGVqoXygXQmIZTl-vSGZ46p7lrRB6pbgWJBqpTN2_mu3MH__6h0IidZR3lhGqsmj9JXasPdFY-_FPeIEfUPnJSG8EDvyASA3QFmTbu5KRBffjFDWzXfS158impgF3zO9yI-3hkLaxGyWpRVM70bX9sLrxypKOrlezTVugWlDklKQjAC53m8SHQjzlKG8c9D86IR-yyzA7gLN23adkSG_GyR9tsgw9f04qxsR0EqoV_MyNvuj3h61i3bq3EHFHllwBmc-Y5WuWtC_damJ9MYLwwFV4usw23VQkmgUFb0Rnpz3YKwB9kybLQE0m1xEhet-WvkuGTgVbxHO6dFYUiWKP0RyOuRjzoSOyuD_abB368S5VAx5Vo29XQGFAbVMDgXQLPdYfVmOeLjOpmVyAKbweP6n6tUKHngI6T6y65PyXQnOheJHLn9a98MwhBKbm4341GOZdOSYrzH-mBnTqO49BuoetwngXre0TTXUK3d_JDNCCny-IhateG4T4zkfodV_XZ7H6zba9dgkFoFJdQLrVsE4gyqW_fDZngUSANoQyAHr3Y8_9uAt7d2MnHXA9LfJZxpP-ho-d_jzj9oz5frk_DYCX6QWIIkcF_ZN501_ld" rel="nofollow" target="_blank">silopharma.com</a></p>  <p><br></br><b>Forward Looking Statements</b><br></br>This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.</p>  <p><b>Contact</b></p>  <p>(800) 705-0120<br></br><a href="https://www.globenewswire.com/Tracker?data=2Ve8mG5CfX9RYMAKJw9WGm433L6Pq5Wk8dGEEkKYQJV3QTrL1hzhCMgalMV68rxMfbX1AuyVrgp4OOGmIp7wllnKvZmShB05d631j6lBvZqqzFmyecq6mHeqRfjPrZ6t7qLr4wb9Qw5q6zfyYq5eflvmcJmWpeCAaeLjlh4p7p52DV1vJgqr6_up_Fpqib-3CiumnFBXVw2XTpY0-CTDj6j9cfMmtxQD6SmRd-DlkiDBjOh7lXfIThuOdNKujdUuidEL6tD_NoLF-RNMt_EQ_eEN9-M0cM4dlGYaaYj4v8l_1apHWCEs7SR8LNa5NtsdA-EHemLZENSzhg52tyi0OSdW2_RyVsPa3SdyV4npqZ-OYfFXWMWQ0x3GuJzywFX5mYf928gRWFJpEL4Sme-9SiGdBG_o3vnKGYXzUGGLMxSB_jaklcAu6CWbscxb6HHEUkL934seAdZM45HajlNPYdNBtCpRwC1yW5GrHGBHR75yHsBG_er5-y1icCdhDcPc0bVmkc6oZBRLoGd04pVrbQ==" rel="nofollow" target="_blank">investors@silopharma.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NzczNDBhYmEtNjkzMy00ZGZmLTliMjUtOWY3ODU3NGJhYzA2LTUwMDA2OTMzOS0yMDI2LTA4LTA2LWVu/tiny/Silo-Pharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b635464-4382-4b8b-8175-39cc32e08050"><img src="https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png" border="0" width="150" height="73" alt="Primary Logo"></img></a></p>

Silo Pharma announced its QwikAgents subsidiary will collaborate with Caylent to build a new AWS-native platform, preserving core features while boosting scalability, security, and performance for enterprise deployment. The arrangement leverages AWS funding programs and Caylent’s cloud expertise, signaling a potential acceleration in QwikAgents’ commercialization and a broader growth path for SILO’s AI initiatives alongside its biopharma programs.

News insight

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

AI summary

Sentiment rationale

Key facts

Corporate Developments